Loading...
NPI 1598999542 · West Mifflin, PA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Christopher Seebruck is a ophthalmology physician provider located in West Mifflin, Pennsylvania. This profile covers 16 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Christopher Seebruck |
| Address | 9970 Mountain View Dr |
| City | West Mifflin |
| State | PA |
| ZIP | 15122 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | May 5, 2009 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.9M |
| Medicaid | $442.2K |
CHRISTOPHER SEEBRUCK’s practice is heavily focused on intravitreal anti-VEGF therapy and retina diagnostics: the top Medicare revenue drivers are J0178 ($1.3M, 44.3% of Medicare revenue) and J2778 ($987K, 33.5% of Medicare revenue), and Medicaid is similarly concentrated with J0178 ($209.5K, 47.2% of Medicaid revenue) and the intravitreal procedure 67028 ($143.4K, 32.3% of Medicaid revenue). High-volume diagnostic imaging codes such as 92235 and 92134 also appear on the Medicare and Medicaid lists, indicating a combined treatment + imaging retina service line rather than a general ophthalmology primary-care model.
Revenue is highly concentrated in a very small set of codes for both payers: the top 3 Medicare codes account for 84.7% of Medicare revenue and the top 3 Medicaid codes account for 89.4% of Medicaid revenue. This concentration means the provider’s financial performance is closely tied to injection volume, the specific drug mix used, and associated retinal imaging services.
On scale, Medicare is the dominant payer for this clinician: total Medicare revenue is $2.9M versus total Medicaid revenue of $442.2K, so the practice derives most of its billed revenue from Medicare while maintaining a secondary Medicaid footprint. The presence of material Medicaid billing means the provider is not single-payer, but Medicare represents the primary revenue base.
National competitive standing on Medicare is mixed but strong in specific niches: J2778 ranks #35 of 1208 providers nationally (97th percentile, described as notably above typical national volume), which places the provider among the higher-volume ranibizumab injectors. At the same time J0178 ranks #588 of 3204 (82th percentile, typical) while imaging and angiography codes show extreme outlier status (92235 rank #20 of 2192, 99th percentile and 92134 rank #519 of 26868, 98th percentile), indicating exceptional activity in retinal diagnostics alongside very high ranibizumab volume.
State-level competitive standing in Medicaid shows the provider as a relatively prominent in-state retina service supplier: J0178 ranks #7 of 41 providers in-state (85th percentile) and 67028 ranks #10 of 99 (91th percentile), with 92134 at #25 of 183 (87th percentile). These ranks indicate the clinician is a meaningful Medicaid competitor for intravitreal injections and retinal imaging within Pennsylvania.
The overall service mix is procedure-heavy with a low relative share of routine E/M revenue: Medicare 99213 produced 309 claims and $15.5K (0.5% of Medicare revenue) and Medicaid 99213 produced 171 claims and $2.4K (0.5% of Medicaid revenue), both small shares compared with injection and imaging codes. That pattern is consistent with a specialty retina practice where revenue is driven primarily by injections and diagnostic imaging rather than office visits.
Tenure data shows an established billing history: NPI enumerated on 2009-05-05 (~17 years ago), which supports the interpretation that these high-volume injection and imaging patterns reflect a stable, long-running specialty practice rather than a transient billing spike. Longevity may be relevant to contracting or network inclusion discussions where continuity of service is valued.
The drug mix suggests a preference for branded anti-VEGF agents over lower-cost alternatives: on Medicare J2778 (ranibizumab) is $987K and ranks notably above typical national volume, while J9035 (bevacizumab) accounts for $14.2K on Medicare and $6.8K on Medicaid. This differential—together with substantial J0178 (aflibercept) revenue—indicates the practice’s reimbursement and utilization profile will be sensitive to formulary, coverage, and reimbursement policies for proprietary intravitreal agents.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,890 | $690 | $1.3M |
| J2778 | Injection, ranibizumab, 0.1 mg | 5,450 | $180 | $987K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,310 | $90 | $203.4K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 3,720 | $30 | $107.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,190 | $90 | $105.6K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 1,060 | $100 | $101K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,750 | $30 | $74.2K |
| J7999 | Compounded drug, not otherwise classified | 230 | $70 | $16K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 310 | $50 | $15.4K |
| J9035 | Injection, bevacizumab, 10 mg | 270 | $50 | $14.2K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 35 | 140 | 830 | $690 | $865.1K |
| J2778 | 12 | 70 | 1,030 | $190 | $417.1K |
| J2777 | 77 | 100 | 7,950 | $30 | $360.2K |
| 67028 | 21 | 180 | 600 | $90 | $87.5K |
| J7999 | 28 | 110 | 100 | $120 | $33.3K |
| 92014 | 37 | 1,570 | 130 | $80 | $21K |
| 99214 | 13,837 | 23,230 | 100 | $80 | $14.5K |
| 92235 | 2 | 70 | 40 | $100 | $10K |
| J9035 | 10 | 60 | 80 | $50 | $8.7K |
| 92134 | 30 | 1,320 | 60 | $30 | $8.4K |
Showing 1–10 of 16
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 930 | $230 | $209.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,610 | $60 | $143.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,080 | $20 | $43.6K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 530 | $30 | $17.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 480 | $30 | $12.4K |
| J2778 | Injection, ranibizumab, 0.1 mg | 200 | $40 | $7.9K |
| J9035 | Injection, bevacizumab, 10 mg | 680 | $10 | $6.8K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 170 | $10 | $2.4K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 10 | $10 | $170 |
| C9257 | Injection, bevacizumab, 0.25 mg | 30 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 7 | 40 | 120 | $340 | $182.5K |
| J2778 | Injection, ranibizumab, 0.1 mg | 4 | 10 | 200 | $120 | $93.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 10 | 100 | 330 | $70 | $85.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 4,939 | 8,870 | 240 | $40 | $56.1K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 324 | 860 | 240 | $40 | $37K |
| J9035 | Injection, bevacizumab, 10 mg | 8 | 50 | 250 | $50 | $33.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 25 | 180 | 290 | $20 | $24.8K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 1,545 | 1,630 | 90 | $30 | $22K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 6 | 20 | 50 | $30 | $11.8K |
| C9257 | Injection, bevacizumab, 0.25 mg | 4 | 10 | 60 | $1 | $20 |
Other providers in the same ZIP code as Christopher Seebruck, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Center For Emergency Medicine Of Western Pennsylvania | PA | Air Ambulance | $7.9M | $47.8M |
| Associates Surgery Centers, LLC | PA | Ambulatory Surgical Clinic/Center | $652.8K | $563.4K |
| Lynette Judy | PA | Nurse Practitioner | $461.1K | $0 |
| Debbie Divenanzo | PA | Anesthesiology Physician | $18.2K | $23.6K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.